Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
{{output}}
3rd-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, have reasonable efficacy in non-small-cell lung cancers (NSCLC) with EGFR mutations. However, the efficacy of osimertinib in NSCLC patients with flui... ...
